Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial, Multicenter, First Line Paclitaxel-Avelumab Treatment for Inoperable Angiosarcoma

NCT03512834 is registered in ClinicalTrials.gov with Sung Yong Oh as lead sponsor.

NCT NCT03512834
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03512834 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial, Multicenter, First Line Paclitaxel-Avelumab Treatment for Inoperable Angiosarcoma
Lead sponsor
Sung Yong Oh
Phase
Phase 2
Overall status
Unknown status
Start date
June 1, 2018
Completion date
May 31, 2023
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

angiosarcoma metastatic